Work

The pipeline of antiviral T‐cell therapy: what's in the clinic and undergoing development

Year: 2019

Type: article

Abstract: Virus-specific T cells allow targeting of multiple pathogens in patients after hematopoietic stem cell transplantation and have demonstrated potential efficacy for cytomegalovirus, Epstein-Barr Virus, and adenovirus. Novel targets may include BK virus, JC virus, varicella zoster virus, human herpesvirus 6, Aspergillus, human parainfluenza virus-3, herpes simplex virus Type I, Zika virus, and mycobacteria. Generation of patient-specific products and third-party products may expand feasibility of therapy.

Source: Transfusion

DOI: 10.1111/trf.15501

Authors: Alyssa Fatic, Nan Zhang, Michael D. Keller, Patrick J. Hanley

Institutions: Children's National, George Washington University, Center for Cancer and Blood Disorders

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Heart, Lung, and Blood Institute